Today's Voice of Kidney Cancer is Dr. Elizabeth (Lisa) Henske, who runs the Henske Lab at Brigham and Women's Hospital and Harvard Medical School in Boston. One of her principal areas of research is chromophobe renal cell carcinoma (chRCC). She's also one of the newest members of the KCCure scientific advisory board. We're grateful to Dr. Henske for donating her time to answer a few questions about her work in chRCC.
The 2018 Genitourinary (GU) Cancers Symposium is a three-day scientific and educational meeting focusing on research and clinical applications in GU cancers (which includes kidney, prostate and bladder). For the second year in a row, KCCure participated in this important kidney cancer conference.
Register today to learn more about how to apply for new kidney cancer funding! Kidney cancer research funding will be provided for the fiscal year 2017 (FY17) through a new, $10 million, stand-alone program in the Department of Defense Congressionally Directed Medical Research Programs.
KCCure's Kidney Cancer Research Priorities were developed in response to a survey conducted for the newly formed Kidney Cancer Research Program (KCRP). Advice and suggestions were gathered from our National Patient Advisory Board and our Scientific Advisory Board.
The Kidney Cancer Research Alliance (KCCure) announced today that their first research grant of $100,000 has been awarded to Dr. Wayne Marasco, at Dana Farber Cancer Center for his proposal: CAR T-Cell Factories that change the Tumor Microenvironment to Achieve RCC Cures.
Help us improve surveillance in kidney cancer by taking the KCCure kidney cancer survey
It's hard to believe how far we've come as an organization in less than one year since our launch. This week, marked another milestone as KCCure was represented, for the first time, at the International Kidney Cancer Coalition Conference (IKCC) in Warsaw, Poland.
ASCO GU is an annual symposium where doctors and members of the cancer community gather from around the world to discuss the latest and greatest in research for Genitourinary (GU) Cancers – which includes kidney cancer. KCCure was honored to be included, along with many other valued advocacy organizations, representing the patient voice.
KCCure talks with Dr. Michael Atkins, Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC about the TIVO-3 trial and what it means for kidney cancer patients.
There are rare subtypes of kidney cancer that don't get enough attention.